Defining the risk of SARS-CoV-2 variants on immune protection.
View / Open Files
Authors
DeGrace, Marciela M
Alisoltani, Arghavan
Bonenfant, Gaston
Boritz, Eli A
Bricker, Traci L
Brown, Liliana
Carreño, Juan Manuel
Darling, Tamarand L
Davis-Gardner, Meredith E
Di, Han
Dittmann, Meike
Doria-Rose, Nicole A
Douek, Daniel C
Ferrari, Guido
Fischer, Will M
Florence, William C
Franks, John
Halfmann, Peter J
Jaroszewski, Lukasz
Jeevan, Trushar
Koren, Eilay
Koup, Richard A
Lemieux, Jacob E
Livingston, Brandi
McElrath, Margaret J
Montefiori, David C
Mühlemann, Barbara
Munt, Jenny E
Niewiadomska, Anna M
O'Dell, Sijy
Pontelli, Marjorie C
Sacharen, Sinai
Schmidt, Stephen D
Sedova, Mayya
Sette, Alessandro
Shen, Xiaoying
Shukla, Maulik
Stumpf, Spencer
Sullivan, Nancy J
Theiler, James
Turner, Samuel A
Vakaki, Maria A
Wang, Li
Wang, Maple
Wang, Wei
Wilks, Samuel H
Ying, Baoling
Zhou, Bin
Publication Date
2022-05Journal Title
Nature
ISSN
0028-0836
Publisher
Springer Science and Business Media LLC
Type
Article
This Version
AM
Metadata
Show full item recordCitation
DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., et al. (2022). Defining the risk of SARS-CoV-2 variants on immune protection.. Nature https://doi.org/10.1038/s41586-022-04690-5
Abstract
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.
Sponsorship
National Institutes of Health (NIH) (via Mount Sinai School of Medicine (MSSM)) (0258-A504-4609)
National Institutes of Health (NIH) (via Mount Sinai School of Medicine (MSSM)) (HHSN272201400008C)
Identifiers
External DOI: https://doi.org/10.1038/s41586-022-04690-5
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335637
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.